vimarsana.com

Page 2 - வழிகாட்டப்பட்டது கதிர்வீச்சு சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ViewRay Announces Election of Karen N Prange to its Board of Directors

Guggenheim slashes price target on ViewRay Inc [VRAY] – find out why

ViewRay Inc. [NASDAQ: VRAY] slipped around -0.51 points on Tuesday, while shares priced at $6.12 at the close of the session, down -7.69%. The company report on May 25, 2021 that American Hospital in Istanbul, Turkey Purchases MRIdian® MRI-Guided Radiation Therapy System. Get the hottest stocks to

ViewRay Reports First Quarter 2021 Results

ViewRay Reports First Quarter 2021 Results News provided by Share this article CLEVELAND, May 6, 2021 /PRNewswire/  ViewRay, Inc. (Nasdaq: VRAY) (the Company ) today announced financial results for the first quarter ended March 31, 2021. First Quarter 2021 Highlights Received seven new orders for MRIdian systems totaling $40.9 million, compared to four new orders totaling $22.6 million in the first quarter of 2020. Total backlog increased to $264.3 million as of March 31, 2021, compared to $230.8 million as of March 31, 2020. Total revenue of $15.5 million primarily from two revenue units, compared to $14.3 million primarily from three revenue units, including one system upgrade, in the first quarter of 2020. Cash burn in the first quarter of 2021 was approximately $28 million, excluding the net proceeds from the January 2021 public offering, compared to approximately $36 million in the first quarter of 2020.

ViewRay Announces Departure of Chief Operating Officer

ViewRay Announces Departure of Chief Operating Officer News provided by Share this article Share this article CLEVELAND, March 15, 2021 /PRNewswire/ ViewRay, Inc. (Nasdaq: VRAY) ( the Company ) today announced that Shahriar Matin, Chief Operating Officer, will leave the Company effective March 31, 2021. Matin was named Chief Executive Officer designate of Cordis in its recently announced divestiture from Cardinal Health to private equity firm Hellman & Friedman. It has been a privilege to work alongside the ViewRay team, and I believe that MRIdian is unequivocally the future of radiation oncology, said Shahriar Matin, Chief Operating Officer. Departing ViewRay is difficult, but I am confident that the team we have built will execute on the opportunity to become standard of care.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.